Treatment Response and Survival
There was no objective response to avelumab or LITT followed by avelumab treatment as determined by mRANO criteria (Kaplan–Meier analysis revealed that the median OS for the 12 patients from the date of enrollment in the study was 12.75 months (95% CI, 4.5–17.5 months; 